New methods for RWE collection and synthesis

Welcome to GetReal

IMI GetReal

Launched in October 2013, GetReal is a three-year project of the Innovative Medicines Initiative (IMI), a EU public-private consortium consisting of pharmaceutical companies, academia, HTA agencies and regulators (e.g., NICE, HAS, EMA and ZIN), patient organisations and SMEs.

GetReal aims to show how robust new methods of RWE collection and synthesis could be adopted earlier in pharmaceutical R&D and the healthcare decision making process. The consortium is doing this by:

  • Bringing together healthcare decision makers, academics, pharmaceutical companies, clinicians, and other societal stakeholders;
  • Assessing existing processes, methodologies, and key research issues;
  • Proposing innovative trial designs and assessing the value of information;
  • Proposing and testing innovative analytical and predictive modelling approaches;
  • Assessing operational challenges and proposing and testing the impact of solutions;
  • Creating new decision making support, and building tools to allow for the evaluation of development programmes and use in the assessment of the value of introducing new treatments;
  • Sharing and discussing deliverables with healthcare decision makers, academics, pharmaceutical companies, clinicians, and other societal stakeholders;
  • Developing training for researchers, healthcare decision makers and societal stakeholders in the public and private sector in order to increase knowledge about various aspects of effectiveness.

Latest News Latest News

PragMagic Launch: an innovative tool to assist pragmatic trial design - webinar 8 June, 2.30-3.30 pm CEST

Posted on April 24, 2017 15:38
On 8 June, 2017 from 14.30-15.30 CEST (13.30-...  

Release final version ADDIS within IMI GetReal 1 project

Posted on April 06, 2017 13:08
The ADDIS software team, as part of Work Package 4...  

WP4 report: best practices and recommendations on evidence synthesis

Posted on March 30, 2017 10:58
The overall aim of GetReal is to evaluate whether ...  

Funding Funding


The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement no [115546], resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies in kind contribution.